期刊文献+

基于GELOX方案诱导化疗的Ⅰ-Ⅱ期结外鼻型K/T细胞淋巴瘤根治性放疗的预后分析 被引量:3

Treatment outcome and prognosis of patients with stage Ⅰ-Ⅱ nasal-type natural killer/T-cell lymphoma receiving induction chemotherapy with GELOX regimen and radical radiotherapy
原文传递
导出
摘要 目的探讨早期结外鼻型NK/T细胞淋巴瘤(ENKTL)接受GELOX(吉西他滨、奥沙利铂、左旋门冬酰胺酶)方案化疗和放疗疗效及影响因素。方法回顾分析2007--2013年间收治的74例ⅠE-ⅡE期ENKTL患者,根据化疗方案及有无放疗分为3个组,A组47例为首选GELOX化疗后根治性放疗,B组10例为其他方案化疗改用GELOX挽救后放疗,C组17例为接受GELOX方案化疗后未放疗。全组化疗中位3周期,放疗中位剂量54.6Gy分20-30次。结果全组化疗后CR率33.8%(其中放疗后为90%),2年OS和PFS分别为88%和79%。A+C组的疗后CR率、2年0s和PFS分别为73%、92%和84%。A组的2年0S和PFS(96%和84%)均高于B组(50%和45%)和C组(47%和40%,P均〈0.05)。单因素分析显示疗前LDH水平升高和化疗后无缓解是OS和PFS的不良预后因素,局部广泛侵犯也是OS的不良预后因素;多因素分析显示化疗后无缓解是OS及PFS的不良预后因素。结论早期ENKTL患者接受GELOX诱导化疗结合根治性放疗可获得良好疗效.但该方案用于单纯化疗和挽救化疗的疗效仍不理想。 Objective To investigate the treatment outcome and prognostic factors in patients with early-stage extranodal nasal-type natural killer/T-cell lymphoma (ENKTL) who underwent chemotherapy with GELOX ( gemcitabine, oxaliplatin, and L-asparaginase) regimen combined with radiotherapy. Methods The clinical data of 74 patients with stage IE-IIE ENKTL who were admitted from 2007 to 2013 were analyzed retrospectively, and based on the chemoradiotherapy regimen and whether they underwent radiotherapy, these patients were divided into three groups. The 47 patients in group A received the preferred chemotherapy with GELOX regimen and then radical radiotherapy;the 10 patients in group B received another regimen at first, then received GELOX as the rescue chemotherapy, and underwent radiotherapy; the 17 patients in group C underwent the chemotherapy with GELOX regimen and did not receive radiotherapy. The median number of cycles of chemotherapy was 3, and the median dose of radiotherapy was 54. 6 Gy in 20-30 fractions. Results The complete response (CR) rate after chemotherapy was 34% and the CR rate after radiotherapy was 90%.The 2-year overall survival ( OS ) and progression-free survival ( PFS ) rates were 88% and 79%, respectively. The CR rate and 2-year OS and PFS rates for group A + C were 73%, 92%, and 84%, respectively. Group A had significantly higher OS and PFS than group B and group C (96%/84% vs. 50%/ 45% and 47%/40% ;all P〈0. 05).The univariate analysis showed that elevated lactate dehydrogenase level and no response after chemotherapy were the adverse prognostic factors for OS and PFS, and extensive local invasion was the adverse prognostic factor for OS. The multivariate prognostic analysis indicated that no response after chemotherapy was the adverse prognostic factor for OS and PFS. Conclusions The patients with early-stage ENKTL can achieve a good outcome after induction chemotherapy with GELOX regimen combined with radical radiotherapy, but this regimen has no ideal efficacy when applied alone or as rescue chemotherapy.
出处 《中华放射肿瘤学杂志》 CSCD 北大核心 2016年第2期140-145,共6页 Chinese Journal of Radiation Oncology
关键词 NK/T细胞淋巴瘤/放射疗法 NK/T细胞淋巴瘤/化学疗法 预后 NK/T cell lymphoma/radiotherapy NK/T cell lymphoma/ chemotherapy Prognosis
  • 相关文献

参考文献19

  • 1Chan JK, Quintanilla-Martinez L, Ferry JA, et al. Extranodal NK/ T-cell lymphoma, nasal type [ A ]//Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues [ M ].Lyon: IARC, 2008 : 285-288.
  • 2Kohrt H, Lee M, Advani R. Risk stratification in extranodal natural killer/T-cell lymphoma [ J]. Expert Rev Anticancer Ther, 2010,10 (9) : 1395-1405.DOI : 10.1586/era. 10. 130.
  • 3张玉晶,胡伟汉,刘慧,陈尔成,任忠敏,夏云飞,崔念基.鼻型NK/T细胞淋巴瘤的临床和预后分析[J].中华肿瘤杂志,2006,28(1):50-53. 被引量:21
  • 4Li YX,Yao B, Jin J, et al. Radiotherapy as primary treatment for stage I E and IIE nasal natural killer/T-cell lymphoma [J] .J Clin Oncol, 2006,24 ( 1 ) : 181-189. DOI : 10.1200/JCO. 2005.03. 2573.
  • 5金晶,李晔雄,姚波,房辉,刘新帆,周立强,吕宁,余子豪.ⅠE~ⅡE期鼻腔NK/T细胞淋巴瘤的放疗效果分析[J].中华放射肿瘤学杂志,2006,15(2):108-113. 被引量:24
  • 6Tham IWK, Lee KM, Yap SP, et al. Outcome of patients with nasal natural killer (NK)/T-cell lymphoma treated with radiotherapy, with or without chemotherapy [ J ]. Head Neck, 2006,28 ( 2 ) : 126- 134. DOI : 10.1002/hed.20314.
  • 7杨勇,张玉晶,林旭滨,王俊杰,林素暇,李群,夏云飞,管迅行,林桐榆.放疗在早期鼻型NK/T细胞淋巴瘤综合治疗中作用及预后分析[J].中华放射肿瘤学杂志,2009,18(4):285-289. 被引量:14
  • 8Wang L, Wang ZH, Chen XQ, et al. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase ( GELOX ) followed by involved-field radiation therapy for patients with stage I E! I1 E extranodal natural killer/T-cell lymphoma. [ J ]. Cancer, 2013, 119 (2) :348-355.DOI : 10.1002/cncr.27752.
  • 9Wang L, Wang WD, Xia ZJ, et al. Combination of gemcitabine, L- asparaginase,and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage I E/I E extranodal natural killer/T cell lymphoma:a retrospective study in a cohort of 227 patients with long-term follow-up [J]. Med Oncol, 2014, 31 ( 3 ) : 860.DOI : 10.1007/s12032-014-0860-4.
  • 10Wang BY, Li XQ, Ma X J, et al. Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type [ J ]. Am J Hematol, 2008,83(10) :795-799.DOI: 10.1002/ajh.21256.

二级参考文献52

  • 1袁智勇,李晔雄,赵路军,高远红,刘新帆,顾大中,钱图南,余子豪.鼻咽非霍奇金淋巴瘤的临床与预后分析[J].中华肿瘤杂志,2004,26(7):425-429. 被引量:16
  • 2金晶,李晔雄,姚波,房辉,刘新帆,周立强,吕宁,余子豪.ⅠE~ⅡE期鼻腔NK/T细胞淋巴瘤的放疗效果分析[J].中华放射肿瘤学杂志,2006,15(2):108-113. 被引量:24
  • 3Prosnitz LR, Mauch PM. Non-Hodgkin's lymphoma// Perez CA, Brady LW,Halperin EC, et al. eds. Principles and Practice of Radiation Oneology, 4th ed. Philadelphia : Lippincott Williams& Wilkins ,2004:2094.
  • 4Huang MJ,Jiang Y, Liu WP, et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Int J Radiat Oncol Biol Phys ,2008,70 : 166-174.
  • 5Wang BY, Lu J J, Ma X J, et al. Combined chemotherapy and external beam radiation for stage ⅠE and ⅡE natural killer T-cell lymphoma of nasal cavity. Leukemia Lymphoma,2007 ,48 :396-402.
  • 6Na II, Kang H J, Park YH, et al. Prognostic factors for classifying extranodal NK/T cell lymphoma, nasal type, as lymphoid neoplasia. Eur J Haematol,2007,79 : 1-7.
  • 7Guo Y,Lu JJ,Ma X,et al. Combined chemoradiation for the management of nasal natural killer ( NK )/T-cell lymphoma : elucidating the significance of systemic chemotherapy. Oral Oncol,2008, 44 : 23-30.
  • 8Li YX,Yao B, Jin J, et al. Radiotherapy as primary treatment for stage Ⅰ E and ⅡE nasal natural killer / T - cell lymphoma. J Clin Oncol,2006,24 : 181-189.
  • 9Jaffe ES, Harris NL, Stein H, et al. Pathology and genetics of tumours of haematopoietic and lymphoid tissues//WHO, eds. World Health Organization classification of tumours. Lyon : IARC, 2001:204-207.
  • 10Pagano L,Gallamini A,Trape G,et al. NIL/T-cell lymphomas'nasal type': an Italian multicentric retrospective survey. Ann Oncol, 2006,17:794-800.

共引文献53

同被引文献29

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部